Scientific article
English

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

ContributorsIncremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP)Working Group
Published inJAMA neurology, vol. 73, no. 12, p. 1417-1424
Publication date2016
Abstract

Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET has clearly demonstrated analytical validity, its clinical utility is debated.

Keywords
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease/diagnosis/diagnostic imaging/metabolism
  • Amyloid beta-Peptides/metabolism
  • Aniline Compounds
  • Cognitive Dysfunction/diagnosis/diagnostic imaging/metabolism
  • Ethylene Glycols
  • Female
  • Humans
  • Male
  • Positron-Emission Tomography/methods/standards
  • Predictive Value of Tests
Citation (ISO format)
Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP)Working Group. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. In: JAMA neurology, 2016, vol. 73, n° 12, p. 1417–1424. doi: 10.1001/jamaneurol.2016.3751
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN2168-6149
480views
2downloads

Technical informations

Creation06/08/2017 1:33:00 PM
First validation06/08/2017 1:33:00 PM
Update time03/15/2023 1:50:09 AM
Status update03/15/2023 1:50:09 AM
Last indexation10/31/2024 7:20:07 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack